EUROPE CIC DRUG MARKET FORECAST 2018-2026

EUROPE CIC DRUG MARKET FORECAST 2018-2026

  • September 2018 •
  • 71 pages •
  • Report ID: 5496008 •
  • Format: PDF
KEY FINDINGS
European countries have shown immense growth in the field of medical sciences and healthcare.The standard quality of life is evidently high in this region and has been altered in the last few years due to the changing needs of society and awareness towards leading a healthy life.

The Europe chronic idiopathic constipation drug market is estimated to grow at a CAGR of 8.96% during the forecast years of 2018-2026.

MARKET INSIGHTS
The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries.The German CIC drugs market is expected to dominate this region by the end of 2026.

The overall CIC drugs market can be segmented into two types: on the basis of the type of prescriptions and the type of drugs.The type of prescriptions can be further divided into over the counter drugs and the doctor prescribed ones.

The drug types are mainly subdivided into linaclotide and lubiprostone. Lubiprostone is a leading drug in this market.

COMPETITIVE INSIGHTS
Major players in the Europe CIC drug market include Progenics Pharmaceuticals Inc, Theravance Biopharma Inc, Cosmo Pharmaceuticals Sa, Valeant Pharmaceuticals International, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc,Eli Lilly And Company, Bayer Ag, Merck Sharp & Dohme,Roche Holding Ag, Pfizer, GlaxoSmithKline,Synergy Pharmaceuticals, Chugai Pharmaceutical, Allergens and Ferring International Center S.A.